Skip to main content
News Geyer 05.2022
PhD student Inga Hochheiser and Prof. Dr. Matthias Geyer
© Johann Saba / UKB

News categories: Publication

New insight into NLRP3-PYD filament formation

highly polar interface residues enable homomeric interaction of NLRP3-PYD filament

The inflammasome is able to sense intrinsic and extrinsic danger signals. Its activation induces an inflammatory response and pyroptotic cell death. ImmunoSensation2 member Prof. Dr. Matthias Geyer and his team, together with colleagues from the University of Cologne, were now able to assign a directionality to NLRP3 filament formation. This finding has the potential to conceivably stop inflammation at the "growing end", and thus bring chronic inflammatory diseases to a halt. The study has now been published in the journal "Science Advances".

If bacteria or viruses attack living cells or other foreign substances are recognized by the cell, the danger sensor NLRP3 is activated. "The protein deposits in the brain, that are characteristic of Alzheimer's disease, the so-called amyloid-ß plaques, can also set NLRP3 in motion," says Prof. Dr. Matthias Geyer from the Institute for Structural Biology at the University Hospital Bonn, referring to earlier studies. As these previous studies by the researchers show, this reaction increasingly fuels itself: The inflammatory reaction triggered by NLRP3 promotes the further deposition of amyloid-ß plaques and contributes significantly to the disease process.

Once activated, several NLRP3 proteins attach to each other and in this way form the nucleus for a thread-like structure at which more and more proteins gather. "The reaction kicks in as soon as about a dozen of the NLRP3 molecules are present," Geyer reports. In theory, an infinite number of NLRP3 molecules can join together and extend the filament further and further. Inga Hochheiser from Prof. Geyer's team has now been able to show the direction in which this filament grows and continues to expand. "We were able to gain these insights using cryo-electron microscopy. This method makes it possible to observe protein molecules with up to 80,000-fold magnification and thus make them directly visible," says Hochheiser.

"Still image" of the NLRP3-PYD filament under the microscope

In tiny steps, the scientist drizzled NLRP3 isolated from cells onto a sample carrier and flash-froze this mixture. This provided the researchers with a kind of "still image" under the cryo-electron microscope. The emerging thread-like structure of NLRP3 molecules arranged side by side was thus visualized. "These individual images made it possible to understand how the filaments elongate, just like in a film," says Hochheiser. As the molecules fall differently on the sample carrier when drizzled, they can be seen from different perspectives under the microscope. These different views can be combined on the computer to create a three-dimensional image. The results showed that the filaments only form in one direction. "This allowed us to visualize part of the inflammatory apparatus and literally read the direction of growth," says Prof. Geyer.

Stopping chronic inflammatory diseases

"The technical challenge was to find the transitions in the thread-like structures and make them visible in the image," says Prof. Dr. Elmar Behrmann from the Institute for Biochemistry at the University of Cologne. "The new findings now allow us to target the growing end of the inflammatory response using antibodies or drugs," Hochheiser explains. This brings the researchers closer to their goal of stopping the further build-up of the inflammatory apparatus and thus counteracting chronic inflammation.


Participating institutions and funding

In addition to the Institute of Structural Biology and the Institute of Innate Immunity of the University Hospital Bonn, the Institute of Biochemistry of the University of Cologne and The Walter and Eliza Hall Institute of Medical Research in Melbourne (Australia) are involved in the study. Measurements were carried out at the research center caesar in Bonn and at the Rudolf Virchow Center at the University of Würzburg. The study was funded by the Else Kröner-Fresenius Foundation and the German Research Foundation.


Publication

Inga V. Hochheiser, Heide Behrmann, Gregor Hagelueken, Juan F. Rodríguez-Alcázar, Anja Kopp, Eicke Latz, Elmar Behrmann & Matthias Geyer: Directionality of PYD filament growth determined by the transition of NLRP3 nucleation seeds to ASC elongation, Science Advances, DOI: https://www.science.org/doi/10.1126/sciadv.abn7583


Contact

Prof. Dr. Matthias Geyer

Institut für Strukturbiologie

Universitätsklinikum Bonn

Tel. +49-228/287-51400

E-Mail: matthias.geyer@uni-bonn.de

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview